Immunotherapeutics

New York, USA, Sept. 04, 2023 (GLOBE NEWSWIRE) -- Cervical Dysplasia Market Size and Share to Rise by 2032, Assesses DelveInsight | Key Companies - GlaxoSmithKline, Merck, Frantz Viral, Brooklyn ImmunoTherapeutics, PapiVax, Inovio …

This section is Partnership Content supplied The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content.…

 -Results from primary analysis conducted in pediatric patients demonstrate dose-dependent and clinically meaningful responses in addition to a favorable safety and tolerability profile- -Harmony, which was designed with a “low and slow”…

NEW YORK, July 15, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced a collaboration with KaliVir Immunotherapeutics…

The Scientific Advisory Board (SAB) combines the expertise of renowned scientific and international key-opinion leaders in the fields of immunology, immuno-oncology, inflammation and immunotherapy.The SAB will work with the Company’s…

NANTES, France, May 23, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) and its clinical partners GERCOR, ARCAGY-GINECO and the FoRT Foundation (Fondazione Ricerca Traslazionale), today announced four…

A Phase 1 Study Sponsored and Conducted by Veloxis Pharmaceuticals, Inc., the Company’s Partner in Transplantation NANTES, France, May 18, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today…

NANTES, France, May 11, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) has been invited to provide an update on its R&D programs in immuno-oncology at two dedicated international conferences in…

A new protection covering CLEC-1 antagonists until 2037Patent also granted in Japan and notice of allowance granted in the US NANTES, France, May 02, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE)…

Positive long term immunological results at 6 months in healthy volunteers with strong T cell memory responses against virus proteins.CoVepiT, based on 13 peptides, elicits durable T-cell immunity against a wide range of structural and…